Specific needs of dopamine neurons for stimulation in order to survive: Implication for Parkinson disease

FASEB Journal

Volumn 27, Issue 9, 2013, Pages 3414-3423

  Michel, Patrick P ^a,b,c   Toulorge, Damien ^a,b,c   Guerreiro, Serge ^a,b,c   Hirsch, Etienne C ^a,b,c  

^a SORBONNE UNIVERSITÉ   (France)

^b INSERM   (France)

^c CNRS   (France)

Author keywords

Calcium; Electrical activity; Neurodegeneration

Indexed keywords

CALCIUM; INOSITOL 1,4,5 TRISPHOSPHATE RECEPTOR; RYANODINE RECEPTOR; TRANSIENT RECEPTOR POTENTIAL CHANNEL 1; VOLTAGE GATED CALCIUM CHANNEL;

CALCIUM MOBILIZATION; CALCIUM SIGNALING; CALCIUM TRANSPORT; CELL LOSS; CELL SURVIVAL; DOPAMINERGIC NERVE CELL; ELECTRIC ACTIVITY; ELECTROSTIMULATION; HUMAN; NERVE CELL EXCITABILITY; NERVE CELL NECROSIS; NERVE DEGENERATION; NERVE STIMULATION; NEUROMODULATION; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SUBSTANTIA NIGRA;

CALCIUM; ELECTRICAL ACTIVITY; NEURODEGENERATION;

ANIMALS; DOPAMINERGIC NEURONS; HUMANS; MODELS, BIOLOGICAL; PARKINSON DISEASE;

EID: 84883357109     PISSN: None     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.12-220418     Document Type: Review

References (102)

1. Dauer, W., and Przedborski, S. (2003) Parkinson's disease: mechanisms and models. Neuron 39, 889-909
2. Corti, O., Lesage, S., and Brice, A. (2011) What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiol. Rev. 91, 1161-1218
3. Ferrer, I., Martinez, A., Blanco, R., Dalfó, E., and Carmona, M. (2011) Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease J. Neural Transm. 118, 821-839
4. Grace, A. A., and Bunney, B. S. (1984) The control of firing pattern in nigral dopamine neurons: single spike firing. J. Neurosci. 4, 2866-2876
5. Kita, T., Kita, H., and Kitai, S. T. (1986) Electrical membrane properties of rat substantia nigra compacta neurons in an in vitro slice preparation. Brain Res. 372, 21-30
6. + conductances in guinea-pig substantia nigra pars compacta neurones. J. Physiol. 466, 727-747
7. Grillner, P., and Mercuri, N. B. (2002) Intrinsic membrane properties and synaptic inputs regulating the firing activity of the dopamine neurons. Behav. Brain Res. 130, 149-169
8. Lee, C. R., and Tepper, J. M. (2009) Basal ganglia control of substantia nigra dopaminergic neurons. J. Neural. Transm. Suppl. 73, 71-90
9. Gonon, F. G., and Buda, M. J. (1985) Regulation of dopamine release by impulse flow and by autoreceptors as studied by in vivo voltammetry in the rat striatum. Neuroscience 14, 765-774
10. Rice, M. E., Patel, J. C., and Cragg, S. J. (2011) Dopamine release in the basal ganglia. Neuroscience 198, 112-137
11. + requires concurrent inactivation of NMDA or AMPA/kainate receptors. J. Neurochem. 78, 163-174
12. Salthun-Lassalle, B., Hirsch, E. C., Wolfart, J., Ruberg, M., and Michel, P. P. (2004) Rescue of mesencephalic dopaminergic neurons in culture by low-level stimulation of voltage-gated sodium channels. J. Neurosci. 24, 5922-5930
13. +. FASEB J. 25, 2563-2573
14. Katsuki, H., Takenaka, C., Kume, T., Kaneko, S., and Akaike, A. (2001) Requirement of neural activity for the maintenance of dopaminergic neurons in rat midbrain slice cultures. Neurosci. Lett. 300, 166-170
15. Katsuki, H., Shibata, H., Takenaka, C., Kume, T., Kaneko, S., and Akaike, A. (2003) N-Methyl-D-aspartate receptors contribute to the maintenance of dopaminergic neurons in rat midbrain slice cultures. Neurosci. Lett. 341, 123-126
16. Lyng, G. D., Snyder-Keller, A., and Seegal, R. F. (2007) Dopaminergic development of prenatal ventral mesencephalon and striatum in organotypic co-cultures. Brain Res. 1133, 1-9
17. Wolfart, J., Neuhoff, H., Franz, O., and Roeper, J. (2001) Differential expression of the small-conductance, calciumactivated potassium channel SK3 is critical for pacemaker control in dopaminergic midbrain neurons. J. Neurosci. 21, 3443-3456
18. + channels alters the firing pattern of dopamine neurons in vivo. J. Neurophysiol. 104, 1726- 1735
19. + channels in rat dorsal root ganglion neurons. J. Cell. Physiol. 212, 348-357
20. + channels in the development of substantia nigra dopamine neurons. PLoS One 7, e51610
21. Lüscher, C., and Slesinger, P. A. (2010) Emerging roles for G protein-gated inwardly rectifying potassium (GIRK) channels in health and disease. Nat. Rev. Neurosci. 11, 301-315
22. Counts, S. E., McGuire, S. O., Sortwell, C. E., Crawley, J. N., Collier, T. J., and Mufson, E. J. (2002) Galanin inhibits tyrosine hydroxylase expression in midbrain dopaminergic neurons. J. Neurochem. 83, 442-451
23. Martel, P., Leo, D., Fulton, S., Bérard, M., and Trudeau, L. E. (2011) Role of Kv1 potassium channels in regulating dopamine release and presynaptic D2 receptor function. PLoS One 6, e20402
24. Liss, B., Haeckel, O., Wildmann, J., Miki, T., Seino, S., and Roeper, J. (2005) K-ATP channels promote the differential degeneration of dopaminergic midbrain neurons. Nat. Neurosci. 8, 1742-1751
25. Michel, P. P., Dandapani, B. K., Knusel, B., Sanchez-Ramos, J., and Hefti, F. (1990) Toxicity of 1-methyl-4-phenylpyridinium for rat dopaminergic neurons in culture: selectivity and irreversibility. J. Neurochem. 54, 1102-1109
26. + channels. J. Neurophysiol. 95, 2590-2601
27. 2 elevation, not ATP depletion. J. Neurosci. 25, 10029-10040
28. Michel, P. P., Ruberg, M., and Hirsch, E. (2006) Dopaminergic neurons reduced to silence by oxidative stress: an early step in the death cascade in Parkinson's disease? Sci. STKE 2006, pe19
29. Guerreiro, S., Ponceau, A., Toulorge, D., Martin, E., Alvarez-Fischer, D., Hirsch, E. C., and Michel, P. P. (2009) Protection of midbrain dopaminergic neurons by the end-product of purine metabolism uric acid: potentiation by low-level depolarization. J. Neurochem. 109, 1118-1128
30. Ekstrand, M. I., Terzioglu, M., Galter, D., Zhu, S., Hofstetter, C., Lindqvist, E., Thams, S., Bergstrand, A., Hansson, F. S., Trifunovic, A., Hoffer, B., Cullheim, S., Mohammed, A. H., Olson, L., and Larsson, N. G. (2007) Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc. Natl. Acad. Sci. U. S. A. 104, 1325-1330
31. Schapira, A. H., and Jenner, P. (2011) Etiology and pathogenesis of Parkinson's disease. Mov. Disord. 26, 1049-1055
32. Lannuzel, A., Ruberg, M., and Michel, P. P. (2008) Atypical parkinsonism in the Caribbean island of Guadeloupe: etiological role of the mitochondrial complex I inhibitor annonacin. Mov. Disord. 23, 2122-2128
33. Good, C. H., Hoffman, A. F., Hoffer, B. J., Chefer, V. I., Shippenberg, T. S., Bäckman, C. M., Larsson, N. G., Olson, L., Gellhaar, S., Galter, D., and Lupica, C. R. (2011) Impaired nigrostriatal function precedes behavioral deficits in a genetic mitochondrial model of Parkinson's disease. FASEB J. 25, 1333-1344
34. Li, X., Patel, J. C., Wang, J., Avshalumov, M. V., Nicholson, C., Buxbaum, J. D., Elder, G. A., Rice, M. E., and Yue, Z. (2010) Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J. Neurosci. 30, 1788-1797
35. Kann, O., and Kovács, R. (2007) Mitochondria and neuronal activity. Am. J. Physiol. Cell Physiol. 292, C641-C657
36. Brosenitsch, T. A., and Katz, D. M. (2001) Physiological patterns of electrical stimulation can induce neuronal gene expression by activating N-type calcium channels. J. Neurosci. 21, 2571-2579
37. Aumann, T., and Horne, M. (2012) Activity-dependent regulation of the dopamine phenotype in substantia nigra neurons. J. Neurochem. 121, 497-515
38. Hirsch, E., Graybiel, A. M., and Agid, Y. A. (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334, 345-348
39. Doo, A. R., Kim, S. T., Kim, S. N., Moon, W., Yin, C. S., Chae, Y., Park, H. K., Lee, H., and Park, H. J. (2010) Neuroprotective effects of bee venom pharmaceutical acupuncture in acute 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced mouse model of Parkinson's disease. Neurol. Res. 32(Suppl. 1), 88-91
40. Alvarez-Fischer, D., Noelker, C, Vulinovi'c, F., Grünewald, A., Chevarin, C., Klein, C., Oertel, W. H., Hirsch, E. C., Michel, P. P., and Hartmann, A. (2013) Bee venom and its component apamin as neuroprotective agents in a Parkinson disease mouse model. PloS One 8, e61700
41. Cho, S. Y., Shim, S. R., Rhee, H. Y., Park, H. J., Jung, W. S., Moon, S. K., Park, J. M., Ko, C. N., Cho, K. H., and Park, S. U. (2012) Effectiveness of acupuncture and bee venom acupuncture in idiopathic Parkinson's disease. Parkinsonism Relat. Disord. 18, 948-952
42. Hirsch, E. C., Graybiel, A. M., Duyckaerts, C., and Javoy-Agid, F. (1987) Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. Proc. Natl. Acad. Sci. U. S. A. 84, 5976-5980
43. Jellinger, K. (1988) The pedunculopontine nucleus in Parkinson's disease, progressive supranuclear palsy and Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 51, 540-543
44. Zweig, R. M., Jankel, W. R., Hedreen, J. C., Mayeux, R., and Price, D. L. (1989) The pedunculopontine nucleus in Parkinson's disease. Ann. Neurol. 26, 41-46
45. Karachi, C., Grabli, D., Bernard, F. A., Tandé, D., Wattiez, N., Belaid, H., Bardinet, E., Prigent, A., Nothacker, H. P., Hunot, S., Hartmann, A., Lehéricy, S., Hirsch, E. C., and François, C. (2010) Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease. J. Clin. Invest. 120, 2745-2754
46. Parain, K., Hapdey, C., Rousselet, E., Marchand, V., Dumery, B., and Hirsch, E. C. (2003) Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine Parkinsonian toxin. Brain Res. 984, 224-232
47. Visanji, N. P., O'Neill, M. J., and Duty, S. (2006) Nicotine, but neither the α4β2 ligand RJR2403 nor an α7 nAChR subtype selective agonist, protects against a partial 6-hydroxydopamine lesion of the rat median forebrain bundle. Neuropharmacology 51, 506-516
48. Quik, M., Perez, X. A., and Bordia, T. (2012) Nicotine as a potential neuroprotective agent for Parkinson's disease. Mov. Disord. 27, 947-957
49. Hernán, M. A., Takkouche, B., Caamaño-Isorna, F., and Gestal-Otero, J. J. (2002) A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann. Neurol. 52, 276-284
50. Thacker, E. L., O'Reill, E. J., Weisskopf, M. G., Chen, H., Schwarzschild, M. A., McCullough, M. L., Calle, E. E., Thun, M. J., and Ascherio, A. (2007) Temporal relationship between cigarette smoking and risk of Parkinson disease. Neurology 68, 764-768
51. De Lau, L. M., and Breteler, M. M. (2006) Epidemiology of Parkinson's disease. Lancet Neurol. 5, 525-535
52. Jeyarasasingam, G., Tompkins, L., and Quik, M. (2002) Stimulation of non-α7 nicotinic receptors partially protects dopaminergic neurons from 1-methyl-4-phenylpyridinium-induced toxicity in culture. Neuroscience 109, 275-285
53. Livingstone, P. D., and Wonnacott, S. (2009) Nicotinic acetylcholine receptors and the ascending dopamine pathways. Biochem. Pharmacol. 78, 744-755
54. Liu, Y., Hu, J., Wu, J., Zhu, C., Hui, Y., Han, Y., Huang, Z., Ellsworth, K., and Fan, W. (2012) α7 nicotinic acetylcholine receptor-mediated neuroprotection against dopaminergic neuron loss in an MPTP mouse model via inhibition of astrocyte activation. J. Neuroinflammation 9, 98
55. Suzuki, S., Kawamata, J., Matsushita, T., Matsumura, A., Hisahara, S., Takata, K., Kitamura, Y., Kem, W., and Shimohama, S. (2013) 3-[(2,4-Dimethoxy) benzylidene]-anabaseine dihydrochloride protects against 6-hydroxydopamine- induced parkinsonian neurodegeneration through α7 nicotinic acetylcholine receptor stimulation in rats. J. Neurosci. Res. 91, 462-471
56. Thomsen, M. S., and Mikkelsen, J. D. (2012) The α7 nicotinic acetylcholine receptor ligands methyllycaconitine, NS6740 and GTS-21 reduce lipopolysaccharide-induced TNF-α release from microglia. J. Neuroimmunol. 251, 65-72
57. Lasaga, M., and Debeljuk, L. (2011) Tachykinins and the hypothalamo-pituitary-gonadal axis: an update. Peptides 32, 1972-1978
58. Bolam, J. P., and Smith, Y. (1990) The GABA and substance P input to dopaminergic neurones in the substantia nigra of the rat. Brain Res. 529, 57-78
59. Halliday, G. M., Gai, W. P., Blessing, W. W., and Geffen, L. B. (1990) Substance P-containing neurons in the pontomesencephalic tegmentum of the human brain. Neuroscience 39, 81-96
60. Reid, M. S., Herrera-Marschitz, M., and Ungerstedt, U. (1991) Effects of intranigral substance P and neurokinin A injections on extracellular dopamine levels measured with microdialysis in the striatum and frontoparietal cortex of rats. J. Neurochem. 57, 970-974
61. Gai, W.P., Halliday, G. M., Blumbergs, P. C., Geffen, L. B., and Blessing, W. W. (1991) Substance P-containing neurons in the mesopontine tegmentum are severely affected in Parkinson's disease. Brain 114(Pt. 5), 2253-2267
62. Salthun-Lassalle, B., Traver, S., Hirsch, E. C., and Michel, P. P. (2005) Substance P, neurokinins A and B, and synthetic tachykinin peptides protect mesencephalic dopaminergic neurons in culture via an activity-dependent mechanism. Mol. Pharmacol. 68, 1214-1224
63. Chu, J. M., Chen, L. W., Chan, Y. S., and Yung, K. K. (2011) Neuroprotective effects of neurokinin receptor one in dopaminergic neurons are mediated through Akt/PKB cell signaling pathway. Neuropharmacology 61, 1389-1398
64. Choi, Y. M., Jang, J. Y., Jang, M., Kim, S. H., Kang, Y. K., Cho, H., Chung, S., and Park, M. K. (2009) Modulation of firing activity by ATP in dopamine neurons of the rat substantia nigra pars compacta. Neuroscience 160, 587-595
65. Michel, P. P., Marien, M., Ruberg, M., Colpaert, F., and Agid, Y. (1999) Adenosine prevents the death of mesencephalic dopaminergic neurons by a mechanism that involves astrocytes. J. Neurochem. 72, 2074-2082
66. Sato, A., Arimura, Y., Manago, Y., Nishikawa, K., Aoki, K., Wada, E., Suzuki, Y., Osaka, H., Setsuie, R., Sakurai, M., Amano, T., Aoki, S., Wada, K., and Noda, M. (2006) Parkin potentiates ATP-induced currents due to activation of P2X receptors in PC12 cells. J. Cell. Physiol. 209, 172-182
67. Thompson, A. A., Liu, W., Chun, E., Katritch, V., Wu, H., Vardy, E., Huang, X. P., Trapella, C., Guerrini, R., Calo, G., Roth, B. L., Cherezov, V., and Stevens, R. C. (2012) Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. Nature 485, 395-399
68. Marti, M., Mela, F., Veronesi, C., Guerrini, R., Salvadori, S., Federici, M., Mercuri, N. B., Rizzi, A., Franchi, G., Beani, L., Bianchi, C., and Morari, M. (2004) Blockade of nociceptin/ orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior. J. Neurosci. 24, 6659-6666
69. Marti, M., Mela, F., Fantin, M., Zucchini, S., Brown, J. M., Witta, J., Di Benedetto, M., Buzas, B., Reinscheid, R. K., Salvadori, S., Guerrini, R., Romualdi, P., Candeletti, S., Simonato, M., Cox, B. M., and Morari, M. (2005) Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease. J. Neurosci. 25, 9591- 9601
70. Marti, M., Sarubbo, S., Latini, F., Cavallo, M., Eleopra, R., Biguzzi, S., Lettieri, C., Conti, C., Simonato, M., Zucchini, S., Quatrale, R., Sensi, M., Candeletti, S., Romualdi, P., and Morari, M. (2010) Brain interstitial nociceptin/orphanin FQ levels are elevated in Parkinson's disease. Mov. Disord. 25, 1723-1732
71. Holmes A, and Picciotto, M. R. (2006) Galanin: a novel therapeutic target for depression, anxiety disorders and drug addiction? CNS Neurol. Disord. Drug Targets 5, 225-232
72. Webling, K. E., Runesson, J., Bartfai, T., and Langel, U. (2012) Galanin receptors and ligands. Front. Endocrinol. (Lausanne) 3, 146
73. Xu, L., Sterling, C. R., and Tank, A. W. (2009) cAMP-mediated stimulation of tyrosine hydroxylase mRNA translation is mediated by polypyrimidine-rich sequences within its 3=-untranslated region and poly(C)-binding protein 2. Mol. Pharmacol. 76, 872-883
74. + channels in the heart. Cell Calcium 40, 205-220
75. Teive, H. A., Troiano, A. R., Germiniani, F. M., and Werneck, L. C. (2004) Flunarizine and cinnarizine-induced parkinsonism: a historical and clinical analysis. Parkinsonism Relat. Disord. 10, 243-245
76. Mena, M. A., and de Yébenes, J. G. (2006) Drug-induced parkinsonism. Expert Opin. Drug Saf. 5, 759-771
77. Adams, D. J., Callaghan, B., and Berecki, G. (2012) Analgesic conotoxins: block and G protein-coupled receptor modulation of N-type (Cav 2.2) calcium channels. Br. J. Pharmacol. 166, 486-500
78. Evans, R. M., You, H., Hameed, S., Altier, C., Mezghrani, A., Bourinet, E., and Zamponi, G. W. (2010) Heterodimerization of ORL1 and opioid receptors and its consequences for N-type calcium channel regulation. J. Biol. Chem. 285, 1032-1040
79. He, X. B., Yi, S. H., Rhee, Y. H., Kim, H., Han, Y. M., Lee, S. H., Lee, H., Park, C. H., Lee, Y. S., Richardson, E., Kim, B. W., and Lee, S. H. (2011) Prolonged membrane depolarization enhances midbrain dopamine neuron differentiation via epigenetic histone modifications. Stem Cells 29, 1861-1773
80. Schulz, J. B. (2007) Mechanisms of neurodegeneration in idiopathic Parkinson's disease. Parkinsonism Relat. Disord. 13, S306-S308
81. Chan, C. S., Guzman, J. N., Ilijic, E., Mercer, J. N., Rick, C., Tkatch, T., Meredith, G. E., and Surmeier, D. J. (2007) 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature 447, 1081-1086
82. Meredith, G. E., Totterdell, S., Potashkin, J. A., and Surmeier, D. J. (2008) Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol. Parkinsonism Relat. Disord. 14(Suppl. 2), S112-S115
83. Ritz, B., Rhodes, S. L., Qian, L., Schernhammer, E., Olsen, J. H., and Friis, S. (2010) L-type calcium channel blockers and Parkinson disease in Denmark. Ann. Neurol. 67, 600-606
84. Pasternak, B., Svanström, H., Nielsen, N. M., Fugger, L., Melbye, M., and Hviid, A. (2012) Use of calcium channel blockers and Parkinson's disease. Am. J. Epidemiol. 175, 627- 635
85. Marras, C., Gruneir, A., Rochon, P., Wang, X., Anderson, G., Brotchie, J., Bell, C. M., Fox, S., and Austin, P. C. (2012) Dihydropyridine calcium channel blockers and the progression of parkinsonism. Ann. Neurol. 71, 362-369
86. Changeux, J. P., and Edelstein, S. J. (1998) Allosteric receptors after 30 years. Neuron 21, 959-980
87. Tsuneki, H., Klink, R., Léna, C., Korn, H., and Changeux, J. P. (2000) Calcium mobilization elicited by two types of nicotinic acetylcholine receptors in mouse substantia nigra pars compacta. Eur. J. Neurosci. 12, 2475-2485
88. Kim, S. R., Ries, V., Cheng, H. C., Kareva, T., Oo, T. F., Yu, W. H., Duff, K., Kholodilov, N., and Burke, R. E. (2011) Age and α-synuclein expression interact to reveal a dependence of dopaminergic axons on endogenous Akt/PKB signaling. Neurobiol. Dis. 44, 215-222
89. Domanskyi, A., Geissler, C., Vinnikov, I. A., Alter, H., Schober, A., Vogt, M. A., Gass, P., Parlato, R., and Schütz, G. (2011) Pten ablation in adult dopaminergic neurons is neuroprotective in Parkinson's disease models. FASEB J. 25, 2898-2910
90. Marinelli, M., and White, F. J. (2000) Enhanced vulnerability to cocaine self-administration is associated with elevated impulse activity of midbrain dopamine neurons. J. Neurosci. 20, 8876-8885
91. Dagher, A., and Robbins, T. W. (2009) Personality, addiction, dopamine: insights from Parkinson's disease. Neuron 61, 502- 510
92. Uslaner, J. M., Smith, S. M., Huszar, S. L., Pachmerhiwala, R., Hinchliffe, R. M., Vardigan, J. D., Nguyen, S. J., Surles, N. O., Yao, L., Barrow, J. C., Uebele, V. N., Renger, J. J., Clark, J., and Hutson, P. H. (2012) T-type calcium channel antagonism produces antipsychotic-like effects and reduces stimulant-induced glutamate release in the nucleus accumbens of rats. Neuropharmacology 62, 1413-1421
93. Verkhratsky, A. (2005) Physiology and pathophysiology of the calcium store in the endoplasmic reticulum of neurons. Physiol. Rev. 85, 201-279
94. Patel, J. C., Witkovsky, P., Avshalumov, M. V., and Rice, M. E. (2009) Mobilization of calcium from intracellular stores facilitates somatodendritic dopamine release. J. Neurosci. 29, 6568- 6579
95. Toulorge, D., Guerreiro, S., Hirsch, E. C., and Michel, P. P. (2010) KATP channel blockade protects midbrain dopamine neurons by repressing a glia-to-neuron signaling cascade that ultimately disrupts mitochondrial calcium homeostasis. J. Neurochem. 114, 553-564
96. Calì, T., Ottolini, D., Negro, A., and Brini, M. (2012) α-Synuclein controls mitochondrial calcium homeostasis by enhancing endoplasmic reticulum-mitochondria interactions. J. Biol. Chem. 287, 17914-1729
97. Guerreiro, S., Toulorge, D., Hirsch, E., Marien, M., Sokoloff, P., and Michel, P. P. (2008) Paraxanthine, the primary metabolite of caffeine, provides protection against dopaminergic cell death via stimulation of ryanodine receptor channels. Mol. Pharmacol. 74, 980-989
98. Xu, K., Xu, Y. H., Chen, J. F., and Schwarzschild, M. A. (2010) Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease. Neuroscience 167, 475-481
99. Satake, W., Nakabayashi, Y., Mizuta, I., Hirota, Y., Ito, C., Kubo, M., Kawaguchi, T., Tsunoda, T., Watanabe, M., Takeda, A., Tomiyama, H., Nakashima, K., Hasegawa, K., Obata, F., Yoshikawa, T., Kawakami, H., Sakoda, S., Yamamoto, M., Hattori, N., Murata, M., Nakamura, Y., and Toda, T. (2011) Genomewide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet. 41, 1303-1307
100. Saad, M., Lesage, S., Saint-Pierre, A., Corvol, J. C., Zelenika, D., Lambert, J. C., Vidailhet, M., Mellick, G. D., Lohmann, E., Durif, F., Pollak, P., Damier, P., Tison, F., Silburn, P. A., Tzourio, C., Forlani, S., Loriot, M. A., Giroud, M., Helmer, C., Portet, F., Amouyel, P., Lathrop, M., Elbaz, A., Durr, A., Martinez, M., and Brice, A.; French Parkinson's Disease Genetics Study Group. (2011) Genome-wide association study confirms BST1 and suggests a locus on 12q24 as the risk loci for Parkinson's disease in the European population. Hum. Mol. Genet. 20, 615-627
101. Selvaraj, S., Sun, Y., and Singh, B. B. (2010) TRPC channels and their implication in neurological diseases. CNS Neurol. Disord. Drug Targets 9, 94-104
102. Selvaraj, S., Sun, Y., Watt, J. A., Wang, S., Lei, S., Birnbaumer, L., and Singh, B. B. (2012) Neurotoxin-induced ER stress in mouse dopaminergic neurons involves downregulation of TRPC1 and inhibition of AKT/mTOR signaling. J. Clin. Invest. 122, 1354-1367